Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.
Revenue of Deciphera Pharmaceuticals, Inc. (DCPH)
Revenue in 2023 (TTM): $163.36 M
According to Deciphera Pharmaceuticals, Inc.'s latest financial reports the company's current revenue (TTM) is $163.36 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Deciphera Pharmaceuticals, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $163.36 M | $159.62 M | $-208,858,000 | $-194,511,000 | $-194,942,000 |
| 2022 | $134.04 M | $125.27 M | $-182,722,000 | $-178,209,000 | $-178,931,000 |
| 2021 | $96.15 M | $93.22 M | $-300,077,000 | $-299,964,000 | $-296,837,000 |
| 2020 | $42.09 M | $41.86 M | $-264,184,000 | $-266,489,000 | $-266,489,000 |
| 2019 | $25 M | $24.17 M | $-192,189,000 | $-192,256,000 | $-191,493,000 |
| 2018 | $ | $ | $-99,770,000 | $-99,854,000 | $-99,854,000 |
| 2017 | $ | $ | $-50,039,000 | $-50,284,000 | $-50,284,000 |
| 2016 | $ | $ | $-25,744,000 | $-25,940,000 | $-25,940,000 |
| 2015 | $ | $ | $-17,534,000 | $-19,816,000 | $-19,816,000 |